Last Price
38.67
Today's Change
-0.01 (0.02%)
Day's Change
38.38 - 39.37
Trading Volume
332,547
Market Cap
2 Billion
Shares Outstanding
59 Million
Avg Volume
671,001
Avg Price (50 Days)
38.88
Avg Price (200 Days)
38.97
PE Ratio
14.11
EPS
2.74
Earnings Announcement
25-Feb-2025
Previous Close
38.68
Open
38.74
Day's Range
38.36 - 39.37
Year Range
24.22 - 48.89
Trading Volume
351,432
1 Day Change
-0.03%
5 Day Change
-0.97%
1 Month Change
1.92%
3 Month Change
-5.94%
6 Month Change
-4.73%
Ytd Change
-0.80%
1 Year Change
36.98%
3 Year Change
34.60%
5 Year Change
350.17%
10 Year Change
230.51%
Max Change
230.51%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.